Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2011

View Archived Issues

Gene therapy shows promise in phase I Leber's congenital amaurosis study

EMA to begin review of Pfizer's tofacitinib MAA for rheumatoid arthritis

Exodos Life Science completes pre-IND meeting for ELS-115

Novel biomarker for ankylosing spondylitis identified

Phase II data reported for LY-2439821 in patients with rheumatoid arthritis

Data from phase III trials support benefits of tofacitinib in rheumatoid arthritis

Maximum tolerated dose of LDE-225 determined in patients with solid tumors

Novel tyrosine-protein kinase SYK inhibitor evaluated in arthritis model

Merck & Co. synthesizes novel M1 receptor positive allosteric modulators

New mGlu2 receptor agonists described by Merck & Co.

Merck & Co. presents novel lysosomal Pro-X carboxypeptidase inhibitors

PharmacoFore discloses new tapentadol prodrugs for pain

Novel modulators of skeletal muscle contractility patented by Cytokinetics

FDA approves Erwinaze for acute lymphoblastic leukemia

Convergence Pharmaceuticals begins phase I study of CNV-2197944

CHMP recommends variation to marketing terms for Nevanac

Phosphagenics begins pivotal TPM/oxycodone patch trials

Merrimack Pharmaceuticals begins enrollment in MM-121/erlotinib combination trial

TONIX Pharmaceuticals obtains FDA clearance to begin TNX-102 trial

Cabozantinib trial begins in hormone receptor-positive breast cancer

Companies collaborate on DNA-based therapy for pulmonary arterial hypertension

Gilead Sciences signs definitive agreement to acquire Pharmasset

GW Pharmaceuticals files application seeking approval of Sativex in more European countries

FDA approves Abbott's supplemental Chagas' disease assay

FDA accepts for review NDA for aripiprazole depot formulation in schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...